# Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

> **NCT03708900** · PHASE2 · RECRUITING · sponsor: **RECORDATI GROUP** · enrollment: 12 (estimated)

## Conditions studied

- Cushing Syndrome

## Interventions

- **DRUG:** LCI699

## Key facts

- **NCT ID:** NCT03708900
- **Lead sponsor:** RECORDATI GROUP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-28
- **Primary completion:** 2027-07-21
- **Final completion:** 2027-07-21
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03708900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03708900, "Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03708900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*